DRUG · Unmapped registry intervention
APL-101 Oral Capsules
Find medicine records ·
Find other trials using this name
Clinical trial
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedAPL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Solid Tumorsunresolved
Advanced Cancerunresolved
Renal Cancerunresolved
Gastric Cancerverified · MONDO: gastric cancer
NSCLCverified · MONDO: non-small cell lung carcinoma
Lung Cancerverified · MONDO: lung cancer
Brain Tumorverified · MONDO: brain neoplasm
Glioblastoma Multiformeverified · MONDO: glioblastoma
EGFR Gene Mutationunresolved
MET Amplificationunresolved
HGFunresolved
Thyroid Cancerverified · MONDO: thyroid cancer
Colon Cancerverified · MONDO: malignant colon neoplasm
MET Alterationunresolved
MET Fusionunresolved
Exon 14 Skippingunresolved
Interventions
Sponsors & collaborators
Apollomics Inc.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03175224 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.